Ngal as a biomarker for predicting the evolution and treatment of chronic kidney disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinase–associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2–/– mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2–/–mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure. Scientific Publication(s): J Clin Invest., 2010 November 1, Viau A. et al., Lipocalin 2 is essential for chronic kidney disease progression in mice and humans, doi: 10.1172/JCI42004

Keywords: Nephrology, Diagnostics, Biomarker, Chronic Kidney Disease, NGAL, Lipocalin 2, EGFR, renal failure
Patent Application number: EP10 306 077.8
Inventors:
Martine BURTINKhalil EL KAROUIFabiola TERZIAmandine VIAUClément NGUYEN
Publications:
J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.

Reference:

BIO10870-D1

Business Developper
contact
Sylvestre CHEA
Sylvestre CHEA
Business Development Manager
Patent filling date: 2010-10-01

You might also be interested in